Po-Kai Chuang

Dr. Po-Kai Chuang

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2025 in Bioorganic Chemistry
Verified
Journal Article
Closed access
KSKung-Yu Shao
Kung-Yu Shao
SLSheng-Dean Luo
Sheng-Dean Luo
EHEng-Yen Huang
Eng-Yen Huang
TCTsung-Ming Chang
Tsung-Ming Chang
LBLavanya Botcha
Lavanya Botcha
PCPo-Kai Chuang
Po-Kai Chuang

Verified
Journal Article
Open access
PDF file
PCPo-Kai Chuang
Po-Kai Chuang
KCKai-Fu Chang
Kai-Fu Chang
CCChih-Hsuan Chang
Chih-Hsuan Chang
TCTing-Yu Chen
Ting-Yu Chen
YWYueh-Jung Wu
Yueh-Jung Wu
TCTung-Yuan Chen
Tung-Yuan Chen
Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide, characterized by high incidence and poor survival rates. Glycosylation, a fundamental post-translational modification, influences protein stability, signaling, and tumor progression, with aberrations implicated in immune evasion and metastasis. This study investigates the role of glycosylation-related genes (Glycosylation-RGs) in CRC using machine learning and bioinformatics. Data from The Cancer Genome Atlas (TCGA) and the Molecular Signatures Database (MSigDB) were analyzed to identify 67 differentially expressed Glycosylation-RGs. These genes were used to classify CRC patients into two subgroups with distinct survival outcomes, highlighting their prognostic value. Weighted gene coexpression network analysis (WGCNA) revealed key modules associated with CRC traits, including pathways like glycan biosynthesis and PI3K–Akt signaling. A machine-learning-based prognostic model demonstrated strong predictive performance, stratifying patients into high- and low-risk groups with significant survival differences. Additionally, the model revealed correlations between risk scores and immune cell infiltration, providing insights into the tumor immune microenvironment. Drug sensitivity analysis identified potential therapeutic agents, including Trametinib, SCH772984, and Oxaliplatin, showing differential efficacy between risk groups. These findings enhance our understanding of glycosylation in CRC, identifying it as a critical factor in disease progression and a promising target for future therapeutic strategies.

29 February 2024 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
PCPo-Han Chen
Po-Han Chen
HLHsein-Kun Lu
Hsein-Kun Lu
TRTing-Yi Renn
Ting-Yi Renn
TCTsung-Ming Chang
Tsung-Ming Chang
CLChia-Jung Lee
Chia-Jung Lee
JLJu-Fang Liu
Ju-Fang Liu
Background/Aim: Oral squamous cell carcinoma (OSCC), a major malignancy in Taiwan, is an invasive epithelial neoplasm resulting in a low survival rate. Current treatments do not prevent OSCC progression, and antitumor therapies should be improved. Plumbagin, a natural compound extracted from Plumbago zeylanica L., appears to have antitumor effects in various tumors. The antitumor mechanism of plumbagin in OSCC is still unclear. This study investigated the molecular mechanism through which plumbagin induces apoptosis. Materials and Methods: To investigate the antiproliferative and pro-apoptotic effects of Plumbagin on OSCC cells and explore its underlying mechanism, cell counting kit-8, cell cycle analysis, and annexin V/PI assay were conducted. The functions of plumbagin on endoplasmic reticulum (ER) stress, reactive oxygen species (ROS) production, and mitochondrial membrane potential (MMP) deficiency were analyzed using flow cytometric analysis. Plumbagin-induced apoptosis-associated proteins were detected using western blotting. Results: Plumbagin induced apoptosis in OSCC cells by suppressing tumor cell proliferation through ROS production, ER stress, mitochondrial dysfunction, and caspases activation. Conclusion: Plumbagin is a promising antitumor candidate targeting human OSCC.

1 January 2025 in American Journal of Cancer Research
Verified
Journal Article
Closed access
CYChih-Jen Yang
Chih-Jen Yang
CCCheng-Hao Chuang
Cheng-Hao Chuang
YCYin-Wen Chen
Yin-Wen Chen
CHChing-Tang Huang
Ching-Tang Huang
PWPei-Hui Wang
Pei-Hui Wang
PCPo-Kai Chuang
Po-Kai Chuang
The complex interplay of TROP2 and PD-L1 in lung adenocarcinoma (LUAD) influences drug resistance and immunotherapy efficacy remains incompletely understood yet. In this study, we investigated the relationship between TACSTD2 (encoding TROP2) and PD-L1 expression through transcriptome analysis, immunohistochemistry, and single-cell RNA sequencing in lung cancer cell lines, tumor tissues, and immune cells, focusing on PC9 parental and drug-resistant variants. TACSTD2 expression strongly correlated with poor clinical outcomes, particularly in immunotherapy-treated patients (HR 1.71 for OS, 2.95 for PFS). Our transcriptome analysis revealed distinct resistance mechanisms involving MAPK signaling and immune receptor regulation pathways. Immunohistochemistry demonstrated significantly elevated TROP2 expression in tumor tissues compared to normal samples, with notably higher levels in PD-L1 positive specimens. We observed significant negative correlations between TACSTD2 expression and CD8+ T cell infiltration (Rho = -0.11, P = 1.44e-02), alongside positive correlations with cancer-associated fibroblasts (Rho = 0.094, P = 3.68e-02). Single-cell RNA sequencing identified two distinct cancer subtypes with differential TACSTD2 expression, while gene ontology analysis highlighted enrichment in cell adhesion and immune interaction pathways. These findings provide novel insights into the molecular mechanisms underlying TROP2 and PD-L1 interactions in LUAD, offering potential new diagnostic markers and therapeutic strategies through improved understanding of tumor microenvironment dynamics and resistance mechanisms.

13 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
PCPo-Kai Chuang
Po-Kai Chuang
KCKai-Fu Chang
Kai-Fu Chang
CCChih-Hsuan Chang
Chih-Hsuan Chang
TCTing-Yu Chen
Ting-Yu Chen
YWYueh-Jung Wu
Yueh-Jung Wu
TCTung-Yuan Chen
Tung-Yuan Chen
Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide, charac-terized by high incidence and poor survival rates. Glycosylation, a fundamental post-translational modification, influences protein stability, signaling, and tumor pro-gression, with aberrations implicated in immune evasion and metastasis. This study investigates the role of glycosylation-related genes (Glycosylation-RGs) in CRC using machine learning and bioinformatics. Data from The Cancer Genome Atlas (TCGA) and the Molecular Signatures Database (MSigDB) were analyzed to identify 67 differentially expressed Glycosylation-RGs. These genes were used to classify CRC patients into two subgroups with distinct survival outcomes, highlighting their prognostic value. Weighted Gene Coexpression Network Analysis (WGCNA) revealed key modules as-sociated with CRC traits, including pathways like glycan biosynthesis and PI3K-Akt signaling. A machine learning-based prognostic model demonstrated strong predictive performance, stratifying patients into high- and low-risk groups with significant sur-vival differences. Additionally, the model revealed correlations between risk scores and immune cell infiltration, providing insights into the tumor immune microenvironment. Drug sensitivity analysis identified potential therapeutic agents, including Trametinib, SCH772984, and Oxaliplatin, showing differential efficacy between risk groups. These findings enhance our understanding of glycosylation in CRC, identifying it as a critical factor in disease progression and a promising target for future therapeutic strategies.

24 September 2025 in Phytochemistry Reviews
Verified
Journal Article
Closed access
PDF file
Waqas AliWaqas Ali
Waqas Ali
MSMisbah Sehar
Misbah Sehar
DNDur-E- Nayab
Dur-E- Nayab
RSRimsha Saeed
Rimsha Saeed
YLYungKuo Lee
YungKuo Lee
PCPo-Kai Chuang
Po-Kai Chuang